Side-by-side comparison

ABT vs BSX — Side-by-side comparison

ABT screens cheaper on EV/FCF, BSX has the higher ROIC, BSX has grown revenue faster over five years, and BSX has the cleaner balance sheet by net debt / EBITDA.

ABT

Abbott Labs

Price

$87.41

Market cap

$230.7B

Day %

N/A

BSX

Boston Scientific

Price

$57.78

Market cap

$154.2B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best
ABT
Target
Abbott Labs$230.7B23.5x31.8x10.0%5.1%16.7%N/A0.5xN/A
BSXBoston Scientific$154.2B29.8x41.6x11.9%15.2%18.2%69.0%-0.4xN/A

ABT implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

31.8x

FCF yield

3.2%

5Y rev CAGR

5.1%

BSX implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

41.6x

FCF yield

2.4%

5Y rev CAGR

15.2%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABT.

Grade C
64
/ 100
Quality Radar0 – 20 per axis

Quality Scorecard

Build-time composite score for BSX.

Grade C
62
/ 100
Quality Radar0 – 20 per axis